Drug Trial Radar · NCT06008756
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
14,550
Planned (sponsor's estimate)
Start
Oct 9, 2023
Primary completion
Nov 29, 2029
Study completion Nov 29, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Aug 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularization.
Conditions
- Arteriosclerosis
- Hypercholesterolaemia
Interventions
Enlicitide DecanoateDrug
Enlicitide Decanoate 20 mg tablet taken by mouth.
PlaceboDrug
Placebo tablet matched to enlicitide decanoate taken by mouth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blinded Period: Time to First Occurrence of Coronary Heart Disease (CHD) Death-Based Major Adverse Cardiovascular Events (MACE)-PlusTime frame: From date of randomization until the date of first occurrence of CHD death-based MACE-plus, assessed up to approximately 6 years
Locations
669 sites in 29 countries. Site status is shown where the registry gives one.
Advanced Cardiovascular - Alexander City ( Site 0156)
Alexander City, Alabama
Central Research Associates ( Site 0118)
Birmingham, Alabama
St. Vincent's Birmingham Hospital ( Site 0181)
Birmingham, Alabama
Central Alabama Research ( Site 0109)
Birmingham, Alabama
Alliance for Multispecialty Research, LLC ( Site 0076)
Daphne, Alabama
G&L Research ( Site 0042)
Foley, Alabama
NextStage Clinical Research - Phoenix - (01) ( Site 0191)
Glendale, Arizona
Synexus Clinical Research US, Inc.-Synexus Clinical Research US, Inc - Central Phoenix ( Site 0066)
Phoenix, Arizona
Medical Investigations Inc. ( Site 0188)
Little Rock, Arkansas
National Heart Institute-Research ( Site 0077)
Beverly Hills, California
UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130)
La Jolla, California
Chemidox Clinical Trials ( Site 0145)
Lancaster, California
Velocity Clinical Research, Westlake ( Site 0039)
Los Angeles, California
Carbon Health - Pasadena ( Site 0149)
Pasadena, California
Carbon Health - San Mateo - Hillsdale Mall ( Site 0151)
San Mateo, California
America Clinical Trials-Research Dept ( Site 0104)
Tarzana, California
Premiere Medical Center ( Site 0093)
Toluca Lake, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 0058)
Torrance, California
University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 0146)
Aurora, Colorado
South Denver Cardiology Associates ( Site 0167)
Littleton, Colorado
Cardiology Associates of Fairfield County, P.C. ( Site 0159)
Stamford, Connecticut
Chase Medical Research, LLC ( Site 0046)
Waterbury, Connecticut
Emerson Clinical Research Institute ( Site 0143)
Washington D.C., District of Columbia
Excel Medical Clinical Trials ( Site 0052)
Boca Raton, Florida
Advanced Pharma Research ( Site 0040)
Cutler Bay, Florida
Alliance for Multispecialty Research, LLC ( Site 0083)
Fort Myers, Florida
Westside Center for Clinical Research ( Site 0049)
Jacksonville, Florida
University of Florida - Jacksonville ( Site 0166)
Jacksonville, Florida
East Coast Institute for Research, LLC ( Site 0031)
Jacksonville, Florida
Jacksonville Center for Clinical Research ( Site 0048)
Jacksonville, Florida
East Coast Institute for Research ( Site 0034)
Lake City, Florida
Columbus Clinical Services ( Site 0026)
Miami, Florida
Miami Cardiac & Vascular Institute-Ambulatory Research ( Site 0059)
Miami, Florida
Inpatient Research Clinic ( Site 0041)
Miami Lakes, Florida
Eminat ( Site 0082)
Miramar, Florida
Ocala Research Institute - Ocala - Southwest 20th Place ( Site 0079)
Ocala, Florida
Progressive Medical Research ( Site 0045)
Port Orange, Florida
St Johns Center for Clinical Research ( Site 0016)
Saint Augustine, Florida
Clinical Site Partners LLC, dba CSP Orlando ( Site 0067)
Winter Park, Florida
The Jones Center Clinical Research ( Site 0032)
Macon, Georgia
Showing 40 of 669 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.